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Mini-Abstract 
High-intensity focused ultrasound (HIFU) is a totally non-invasive ablation treatment 
for hepatocellular carcinoma. The complete tumor ablation rate was 79.5%. The 
1-year survival rate was 87.7%. 
Abstract 
Objective: This study aims to evaluate the outcome of patients with 
hepatocellular carcinoma (HCC) treated by high-intensity focused ultrasound (HIFU) 
in a single tertiary referral center. 
Summary Background data: HIFU is the latest developed local ablation 
technique for unresectable HCC. The initial experience on its efficacy is promising, 
but the survival benefit of patients undergoing HIFU for HCC is poorly defined. 
Methods: From October 2006 to December 2008, 49 patients received HIFU for 
unresectable HCC. Each patient underwent a single session of HIFU with a curative 
intent. Treatment efficacy and survival outcome were evaluated. Clinicopathologic 
factors affecting the primary technique effectiveness and overall survival rates were 
investigated by univariate analysis.   
Results: The median size of the treated tumors was 2.2 cm, ranging from 0.9 cm 
to 8 cm. The majority of patients had single tumors (n = 41, 83.6%). Thirty one 
patients (63.2%) had artificial right pleural effusion during HIFU treatment to reduce 
damage to the lung and diaphragm. The hospital mortality rate was 2% (n = 1) and 
the complication rate was 8.1% (n = 4). The primary technique effectiveness rate was 
79.5% (39 out of 49 patients). It increased from 66.6% in the initial series to 89.2% in 
the last 28 patients. Tumor size ( 3.0 cm) was the significant risk factor affecting the 
complete ablation rate. The 1- and 3-year overall survival rates were 87.7% and 
62.4%, respectively. Child-Pugh liver function grading was the significant prognostic 
factor influencing the overall survival rate. 
Conclusions: HIFU is an effective treatment modality for unresectable HCC 
with a high technique effectiveness rate and favorable survival outcome. 
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Introduction 
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, with a high 
prevalence in Asia and an increasing incidence in Western countries. With advancement in 
technologies, local ablation therapies have emerged as effective treatment options for 
unresectable HCC. These include cryoablation therapy, interstitial laser therapy, microwave 
coagulation, radiofrequency ablation (RFA), and high-intensity focused ultrasound (HIFU). 
Among these treatment options, HIFU is the only treatment modality that is completely 
extracorporeal.  
HIFU is based on the unique characteristic of ultrasound beams (0.8 – 3.5 MHz), which 
can be focused at a distance from the radiating transducer. The accumulated energy at the 
focal region induces tissue necrosis of the targeted lesion without causing damage to the 
surrounding vital structures. The ability of inducing immediate cell death at a distance from 
the ultrasound source without the need of surgery or insertion of ablation instruments makes 
HIFU an attractive treatment option for HCC. While data on the efficacy of HIFU in treating 
HCC remain scarce, initial clinical results obtained from pioneer researchers in China have 
been encouraging.1-7 The reported complete ablation rates ranged from 28.5% to 68%.1,6,7  
The short-term survival (one-year) rates ranged from 42.9% to 61.5%.1,4 However, there is no 
report on identification of the possible risk factor affecting the complete ablation rate and the 
possible prognostic factor influencing the overall survival. Such information is crucial in 
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establishing the role of HIFU in the management of patients with HCC. The present study 
aims to evaluate the clinical outcome of patients with HCC treated by HIFU, and investigate 
the clinicopathologic factors affecting the complete ablation rate of HIFU and patient 
survival.  
 
Methods 
Selection of patients 
From October 2006 to December 2008, 49 patients with unresectable HCC received 
HIFU treatment. Patients with advanced diseases due to tumor invasion to major intrahepatic 
blood vessels or extrahepatic metastasis were not selected for the treatment. Patients with 
HCC that could not be visualized by diagnostic ultrasound of the HIFU system were also 
excluded. Diagnosis of HCC was based on radiological features shown by computed 
tomography scan or magnetic resonance imaging (MRI) scan and/or raised serum 
-fetoprotein concentration (over 400 g/ml). A tumor was considered unresectable if the 
patient had unsatisfactory liver function or if there was a high medical risk for the patient to 
undergo hepatic resection. The selection criteria for HIFU were as follows: (1) The maximal 
tumor diameter was less than 8 cm. (2) The number of tumor nodules was less than 3. (3) The 
tumor could be detected by ultrasound imaging and there were no bowel adjacent to the tumor.   
Each selected patient underwent a single session of HIFU aiming at complete ablation of all 
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detected tumors. A total of 57 tumors were ablated. During the initial phase of the study 
period (from October 2006 to May 2007), 21 patients had transarterial injection of iodized 
poppyseed oil (Lipiodol) into their tumors about two weeks before HIFU treatment because 
previous researchers suggested that Lipiodol could reduce tumor blood supply and increase 
the deposition of ultrasonic energy in the tumor. In the later phase of the study (from June 
2007 to December 2008), 28 patients received HIFU only. 
 
Treatment procedures 
The JC HIFU system (Chongqing Haifu Technology, Chongqing, China) was used in 
this study. The ablation process was guided by real-time ultrasound imaging. This system is 
composed of a real-time diagnostic ultrasound device, an integrated ultrasound therapy 
transducer (12 cm in diameter), a six-directional therapeutic planning system, an ultrasound 
generator, a degassed water circulation unit, and a computer unit for automated master control. 
The focused ultrasound was produced by the transducer operating at 0.8 MHz (aperture 120 
mm, focal length 150 mm). The target lesion was identified using a central 3.5-MHz 
diagnostic ultrasound probe, which was integrated in the center of the therapeutic transducer. 
Both diagnostic and therapeutic ultrasound beams were emitted simultaneously in the same 
direction. 
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In patients receiving pre-HIFU Lipiodol deposition into their tumors, hepatic 
angiography was performed two weeks before HIFU treatment. Lipiodol was delivered via 
selective cannulation of the feeding artery of the target tumor. 
HIFU treatment was performed under general anesthesia to alleviate deep visceral pain 
caused by HIFU and to ensure immobilization of patients. Temporary inspiratory or 
expiratory control by the anesthesiologist helped to minimize liver movement caused by 
ventilation during the treatment.8 In selected patients with a tumor at the dome of the liver, 
artificial right pleural effusion was induced before treatment. Detailed planning was carried 
out according to the tumor size and location as detected by the diagnostic ultrasound 
transducer. Parallel slides of the target tumor with 5-mm separation were obtained. Using 
provisional therapeutic parameters based on the depth and vascular supply of the target tumor, 
tissue of each tumor slide was completely ablated from deep to superficial region by 
successful sweeps of the HIFU head. The ablation process was repeated slide by slide to 
achieve entire tumor ablation. During the ablation process, grey-scale changes were noted in 
the ablation zone, signifying the effectiveness of ablation. 
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Data collection and outcome measures 
Clinical details of all 49 patients were prospectively collected in a database. Clinical 
parameters included patient demographics, tumor characteristics, and treatment parameters 
(total treatment duration and acoustic power). Short-term outcome measures were post-HIFU 
complication rate, hospital mortality, and tumor responses. A complication was defined as 
any adverse event after HIFU, and hospital mortality was defined as any death in the same 
admission for the procedure. Tumor responses were classified as the primary technique 
effectiveness rate and secondary technique effectiveness rate, according to the 
recommendation by the international Working Group on Image-guided Tumor Ablation9. The 
primary technique effectiveness rate was defined as the percentage of tumors that were 
successfully eradicated following the initial course of HIFU, whereas the secondary technique 
effectiveness rate was defined as the percentage of tumors that have undergone successful 
repeat ablation following identification of local tumor progression. Tumor response to HIFU 
was assessed by MRI, which was performed one month after the procedure. Successful tumor 
ablation was defined as complete absence of hyperintensity signal in T2W images and 
absence of contrast enhancement within the original tumor region (Figure 1). Any 
contrast-enhancing area within the original tumor region on post-ablation MRI scan indicated 
a residual tumor. RFA or chemoembolization was performed in selected patients to treat 
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residual tumors. All patients had monitoring of serum -fetoprotein concentration, chest 
radiograph and MRI scan every three months to detect tumor recurrence. 
 
Statistical analysis 
Continuous data were expressed as medians with ranges and were compared using the 
Mann-Whitney U test. Categorical data were compared using the χ2 test with Yates correction 
or Fisher exact test where appropriate. The overall and disease-free survival rates were 
calculated by the Kaplan-Meier method and compared between the groups using the log-rank 
test. The end-point of disease-free survival was recurrence of HCC at or outside of the 
ablation site or death of the patient, but excluding hospital mortality. Clinicopathologic 
variables were analyzed for their effects on the primary technique effectiveness and overall 
survival rates. Host factors included age, gender, hepatitis B surface antigen status, 
anti-hepatitis C antibody status, Child-Pugh liver function grading10, serum bilirubin level, 
serum albumin level, platelet count, and previous treatment (hepatectomy, RFA or 
transarterial chemoembolization). Tumor factors included maximum tumor size, number of 
tumors (solitary vs. multiple) and serum -fetoprotein level. Finally, the practice of pre-HIFU 
Lipiodol deposition, the use of artificial right pleural effusion, and the primary and secondary 
technique effectiveness were included in the analysis of overall survival. For the significant 
continuous variables identified by the univariate analysis, the cut-off value was determined 
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using the discriminant analysis. All statistical analyses were performed using the statistical 
software SPSS 11.0 for Windows (SPSS Inc., Chicago, IL). A P-value of less than 0.05 was 
considered statistically significant. 
 
Results 
Patient characteristics 
The demographic and clinicopathologic data of all 49 patients treated by HIFU are 
shown in Table 1. Among the 49 patients, 37 patients (76%) were hepatitis B carriers and 7 
patients (14%) were hepatitis C carriers. The majority of patients (n = 41, 83.6%) had 
preserved liver function (Child-Pugh class A). These patients had high medical risks 
(presence of co-morbidities) to undergo hepatic resection for HCC. Another 8 patients had 
marginal liver function (Child-Pugh class B) that prohibited major hepatic resection of tumors. 
Liver transplantation was not offered to them because of the local policy of offering scarce 
deceased organs to patients with Child-Pugh class C liver function only. HIFU was performed 
for intrahepatic recurrent tumors in 17 patients and 14 patients following hepatectomy and 
RFA, respectively. Eighteen patients (36%) received HIFU for tumors that failed previous 
transarterial chemoembolization. Twenty-eight patients (57.1%) received HIFU as the 
primary treatment for their newly diagnosed HCC. The median tumor size was 2.2 cm (range, 
0.9 – 8 cm). The majority of patients (n = 41, 83.6%) had solitary tumors. Artificial right 
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pleural effusion was induced before HIFU treatment in 31 patients (63%) with tumors near to 
the diaphragm to reduce damage to the lung and diaphragm by heat generated during the 
treatment. The median HIFU treatment duration was 26 minutes (range, 3 – 124 minutes). 
 
Short-term outcome 
One patient in the early part of the series died of myocardial infarction one day after 
HIFU treatment. This patient had underlying ischemic heart disease, which was not diagnosed 
before the HIFU treatment. The hospital mortality rate was 2%. The treatment-related 
complication rate was 8.1% (n = 4). The complications included first-degree and 
second-degree skin burn around the treatment zone in 2 patients and 1 patient, respectively. 
These complications were due to an error of using high acoustic power. One patient 
developed bruising over the right chest wall, extending to the right loin region. This was 
caused by bleeding from intercostal vessels that were injured during induction of artificial 
pleural effusion. The median hospital stay was 4 days (range, 2 – 16 days) (Table 2). 
Ten patients (20.4%) had residual tumors detected by MRI one month after the treatment. 
The primary technique effectiveness rate was 79.5% (39 of 49 patients). Taking into 
consideration the total number of ablated tumor nodules, the primary technique effectiveness 
rate was 82.4% (47 out of 57 nodules). Four patients received percutaneous RFA treatment 
for residual tumors and three of them were rendered tumor-free after RFA. Another 4 patients 
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having residual tumors underwent transarterial chemoembolization but tumor control was 
incomplete. The overall secondary technique effectiveness rate after HIFU and RFA was 
85.7% (42 out of 49 patients). 
Table 3 showed the results of univariate analysis on the possible risk factors for 
incomplete ablation after HIFU treatment. Tumor size was the only significant risk factor 
affecting the primary technique effectiveness rate of HIFU. Patients with primary technique 
effectiveness had significantly smaller tumors than those with residual tumors after HIFU 
treatment (median tumor size: 2.29 cm vs. 3.75 cm, P = 0.013). The cut-off value of tumor 
size as the significant risk factor for incomplete ablation by HIFU was 3.0 cm. The primary 
technique effectiveness for tumors < 3.0 cm was 90.6% (29 out of 32 patients), whereas that 
for tumors  3.0 cm was 58.8% (10 out of 17 patients). The primary technique effectiveness 
rate of patients with HIFU alone (89.2%) was higher than that of those with HIFU and 
pre-treatment Lipiodol deposition (66.6%), although the difference was not significant 
statistically.  
 
Tumor recurrence and survival outcome 
The median follow-up period was 24 months (range, 3 – 38 months). Among the 42 
patients with tumors completely ablated by primary and secondary techniques, 9 patients 
(21.4%) developed local recurrence at the HIFU treatment zone. The long-term local tumor 
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control rate is 67%. All the 9 patients with local tumor recurrence belonged to the group in 
which HIFU treatment was preceded by Lipiodol deposition. On the other hand, all patients 
treated by HFIU alone did not develop local tumor recurrence at the site of HIFU treatment. 
Seventeen patients (40.4%) had intrahepatic tumor recurrence (away from the ablation site). 
Four patients (9.5%) developed extrahepatic metastasis. The overall recurrence rate was 
61.9% (26 out of 42 patients). The 1- and 3-year overall survival rates were 87.7% and 62.4%, 
respectively (Figure 2). The 1- and 3-year disease-free survival rates were 40.7% and 0%, 
respectively (Figure 3). Among the clinicopathologic factors, Child-Pugh grade was the only 
significant prognostic factors influencing overall survival. The overall 1- and 3-year survival 
rates of the patients with Child-Pugh class A were 90.2% and 68.5%, respectively, whereas 
those of the patients with Child-Pugh class B were 75% and 33.3%, respectively (P = 0.028). 
The overall survival rates of patients with secondary technique effectiveness (1-year survival 
rate: 92.9%; 3-year survival rate: 66.8%) were better than those of the patients with residual 
tumors after sequential local ablation (1-year survival rate: 53.6%; 3-year survival rate: 
35.7%) (P=0.06) (Table 4). 
 
Discussion 
HIFU is a newly developed non-invasive treatment modality for liver tumors. Compared 
with other local ablation therapies, HIFU treatment has the major advantage of being totally 
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extracorporeal without the need of insertion of any ablation needle in the target lesion. With 
high acoustic intensities (up to 10,000 Watt/cm2), HIFU induces instantaneous cell death by 
two major mechanisms, namely, thermal effect and mechanical effect.11 The thermal effect of 
HIFU features heat generation due to absorption of acoustic energy by the target tissue. A 
lethal temperature of up to 60C causes coagulative necrosis within a few seconds. Since 
high-intensity energy is focused at a small volume, damage to tissues between the transducer 
and the target lesion is minimized. The mechanical effect involves cavitation12, 
microstreaming13 and radiation forces14. With these destructive mechanisms, irreversible cell 
death occurs through coagulative necrosis and apoptosis. 
The application of HIFU technology in the management of patients with HCC is still in 
its infancy period. The feasibility and safety of HIFU for liver tumors were initially 
demonstrated in the early 1990s.11 However, this technology has not gained much enthusiasm, 
primarily because of the difficulties in tumor targeting and monitoring of the ablation process. 
However, with recent advances in the ultrasound technology, the accuracy of targeting of 
HIFU has improved considerably. 
The initial experience of HIFU for HCC was obtained from researchers in China using 
the JC HIFU system, which was also used in the present study. In a study by Wu et al1 in 
which 55 patients with large HCC (with a mean diameter of 8.14 cm) and cirrhosis received 
HIFU treatment, no major complications were recorded. Completeness of ablation was 
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assessed in 26 patients and the complete ablation rate was 69.2%. The overall survival rates 
were 61.5% at 12 months and 35.3% at 18 months. In another study by the same group4, the 
efficacy of HIFU combined with chemoembolization was compared with that of 
chemoembolization alone in 50 patients with advanced HCC. Patients who underwent 
combined treatment had significantly better survival than those who received 
chemoembolization alone. In the Western population, the efficacy of this HIFU system in 
treating liver tumors has also been validated.15 In this study, the effectiveness of HIFU was 
confirmed and a higher primary technique effectiveness rate (79.5%) was achieved. 
Although the treatment efficacy and survival benefits of HIFU for patients with liver 
cancer were well documented in the previous studies1-7, clinicopathologic factors influencing 
the completeness of tumor ablation and patient survival were not studied in detail. We found 
that tumor size ( 3.0 cm) was a significant risk factor accounting for incomplete tumor 
ablation after HIFU. Although HIFU has the merit of being extracorporeal in nature, the 
portion of skin and subcutaneous tissue along the pathway of focused ultrasound was 
frequently affected, causing tissue edema. As large tumors require longer ablation time by the 
HIFU machine, the resulting cutaneous and subcutaneous tissue edema will reduce the 
targeting ability of the diagnostic ultrasound of the HIFU machine. Hence, the precision of the 
deposition of focused ultrasound onto the target lesion will be negatively affected. As shown 
in our study, patients with residual tumors after a single session of HIFU treatment had 
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significantly larger tumors (median tumor size: 3.75 cm vs. 2.29 cm). Large tumors may, 
therefore, need “planned” repeated HIFU treatment or a second treatment once a residual 
lesion is detected by imaging. 
Apart from tumor size, the use of pre-treatment Lipiodol deposition was another possible 
factor affecting the completeness of tumor ablation. In the treatment protocol of HIFU 
designed by researchers in China, Lipiodol deposition via hepatic angiography is usually 
combined with this ablation technique.1,4 Theoretically, Lipiodol deposition in the tumor can 
increase the ablation volume of HIFU by two possible mechanisms. First, tumor blood flow 
decreases after Lipiodol occlusion of tumor microvasculatures, resulting in reduced heat loss 
during thermal treatment by HIFU. Second, Lipiodol deposition in the tumor causes increased 
deposition of ultrasonic energy.16 Nevertheless, the administration of Lipiodol shortly before 
HIFU is not without disadvantages. In fact, non-specific deposition of Lipiodol within the 
same liver segment as the target tumor invariably affected ultrasound localization of the 
tumor and hence the targeting accuracy of HIFU because the affected liver segment was also 
filled with Lipiodol (Figure 4). In such instance, tumor margins could only be poorly defined 
by the diagnostic ultrasound. Moreover, the non-tumorous liver parenchyma within the 
acoustic window might be involved in the HIFU ablation process because non-specific 
deposits of Lipiodol could absorb high-intensity ultrasonic energy. It could be disastrous if 
any vital vasculatures or the biliary system were within this acoustic window.  
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We postulated that HIFU without Lipiodol deposition might be more effective than the 
combined-treatment approach in terms of completeness of ablation, provided that tumor 
margins could be clearly defined by the HIFU system. With this assumption, we modified the 
treatment protocol of HIFU in the later phase of our study by adopting the HIFU-alone 
treatment. The effectiveness of HIFU-alone approach was supported by the finding of our 
study. The primary technique effectiveness rate of patients with HIFU alone (89.2%) was 
higher than that of those with HIFU and pre-treatment Lipiodol deposition (66.6%, P = 0.076). 
Such high complete ablation rate is comparable with that achieved by RFA17-21, the most 
commonly used local ablation technique for HCC at present. It should be emphasized that 
meticulous techniques are necessary to ensure complete ablation of the tumor in the 
HIFU-alone approach. It is important to carry out pre-HIFU planning using diagnostic 
ultrasound to ensure that the liver tumor is clearly visible before administering HIFU. We 
believe that complete tumor ablation can be achieved by ultrasonic energy using the HIFU 
system alone as long as tumor margins can be clearly defined during the procedure.  
We identified that the Child-Pugh grade was the prognostic factors influencing the 
overall patient survival. This is compatible with the natural course of disease and the patients’ 
suboptimal liver function may not allow them to receive further treatments. Meanwhile, 
patients with secondary technique effectiveness tended to have better overall survival than 
those with residual tumors after sequential local ablation. The assessment of completeness of 
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ablation after HIFU was an important step in our series. Every patient had MRI scan after 
treatment to document the completeness of tumor ablation.22 The advantage of MRI over 
computed tomography scan is that assessment of tumor viability will not be influenced by the 
deposition of Lipiodol in the case that pre-treatment Lipiodol deposition has been performed. 
With accurate assessment, aggressive treatment for any residual tumors after HIFU can be 
carried out without any delay as long as their liver function is optimal. In our study, 
percutaneous RFA was performed in 4 of 10 patients with residual tumors after HIFU, 
making the overall secondary technique effectiveness rate 85.7%. Repeated HIFU treatment 
to residual tumors was not performed in this series. In the future, with accumulation of 
experience, repeated HIFU for residual tumors may be the treatment of choice. Although 
HIFU for HCC is still not widely accepted in many centers, the high treatment efficacy of the 
HIFU-alone approach should not be underestimated. Hence, HIFU treatment can be 
considered as one of the effective treatment options in the setting of current tumor ablation 
technology. In particular, a multidisciplinary approach using different tumor ablation 
techniques might be the future direction of management of HCC patients. 
Our study has confirmed the efficacy of HIFU for patients with HCC. However, HIFU is 
not without complications. Compared with a recent reported series23, the complication rate of 
the present series is lower (8.1%). First and second degree skin burn is especially disturbing. 
Further refinement of the technique, such as artificial ascites24 and intermittent delivery of 
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acoustic energy to allow skin cooling, has been introduced in our recent practice. Their 
efficacy will be evaluated in future reports. 
This study, a retrospective data analysis, has two limitations, namely, a relatively short 
follow-up period and a small patient number. Nevertheless, it has provided an insight into a 
new direction for ablation treatment for HCC. The protocol of HIFU without prior Lipiodol 
deposition can benefit patients with a higher rate of tumor control, making HIFU a favorable 
non-invasive treatment option. In this study, we used the JC HIFU system, which relies on 
ultrasound for tumor targeting and ablation monitoring. The problem of reduction in targeting 
ability of diagnostic ultrasound of this system by cutaneous and subcutaneous tissue edema 
can be overcome by using MRI guidance, which relies on the temperature change of the 
ablated area as the targeting index. As the MRI-guided HIFU system is coming into clinical 
practice,25 comparison of these two systems on efficacy of ablation will be another future goal 
in the evaluation of HIFU for HCC patients. 
In conclusion, HIFU is an effective treatment modality for unresectable HCC with a high 
technique effectiveness rate and favorable survival outcome. Further studies to compare its 
effectiveness with other ablation modalities are warranted.
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Figure legends 
Figure 1 MRI scan shows a 2.7-cm segment VIII HCC before (a) and after (b) HIFU 
treatment. Arrow indicates the tumor impinging on the middle hepatic vein 
before HIFU treatment. Complete ablation was achieved after a single session 
of HIFU treatment without pre-treatment Lipiodol deposition. 
Figure 2 Overall survival rate of 49 patients after HIFU treatment. 
Figure 3 Disease-free survival rate of 48 patients after HIFU treatment. 
Figure 4 CT scan shows non-specific deposition of Lipiodol in the left liver after 
transarterial administration. Arrow indicates the target tumor. 
 
 Table 1.  Demographic and clinicopathologic data of 49 patients treated by HIFU. 
 
Characteristics Values 
Age, years, median (range) 65 (44 – 84) 
Sex ratio, M : F 40 : 9 
Hepatitis B surface antigen positive 37 (76) 
Hepatitis C virus antibody positive 7 (14) 
Child-Pugh liver function classification  
Class A 41 (84) 
Class B 8 (16) 
Serum bilirubin, mol/L, median (range) 16 (4 – 46) 
Serum albumin, g/L, median (range) 38 (24 – 45) 
Platelet count (×109/L), median (range) 103 (26 – 268) 
Previous hepatic resection 17 (35) 
Previous transarterial chemoembolization 18 (36) 
Previous radiofrequency ablation 14 (29) 
Serum -fetoprotein, g/ml, median (range) 11 (2 – 8840) 
Size of largest tumor, cm, median (range) 2.2 (0.9 – 8) 
Number of tumors treated (solitary / 2 lesions) 41 / 8 
Pre-HIFU Lipiodol deposition in tumor 21 (43) 
Artificial right pleural effusion during HIFU 31 (63) 
Total treatment duration, min, median (range) 26 (3 – 124) 
Average acoustic power, watt, median (range) 376 (155 – 473) 
Values are numbers of patients (percentage) unless stated otherwise. 
Table
 Table 2.  Short-term results after HIFU treatment in 49 patients with HCC. 
 
Characteristics Values 
Hospital mortality 1 (2) 
Treatment-related complications 4 (8.1) 
First-degree skin burn 2 
Second-degree skin burn 1 
Chest wall bruising 1 
Hospital stay, days, median (range) 4 (2 – 16) 
Primary technique effectiveness ratea 39 (79.5) 
Primary technique effectiveness rateb 47 (82.4) 
Values are numbers of patients (percentage) unless stated otherwise. 
a. Complete tumor ablation in number of patients (percentage) 
b. Complete tumor ablation in number of tumor nodules (percentage) 
 Table 3.  Univariate analysis on possible risk factors for incomplete ablation after HIFU. 
Factors Complete ablation P value 
 Yes  
(n=39) 
No  
(n=10) 
 
Age, years, median (range) 65 (44 – 81) 68.5 (48 – 84) 0.275 
Sex ratio, M : F 31 : 8 9 : 1 0.663 
Hepatitis B infection 28 (71.7) 9 (90) 0.414 
Hepatitis C infection 6 (15.3) 1 (10) 1.000 
Child-Pugh liver function 
   class A : class B 
 
34 : 5 
 
7 : 3 
 
0.333 
Serum bilirubin, mol/L, median (range) 16 (4 – 44) 14 (8 – 46) 0.673 
Serum albumin, g/L, median (range) 39 (24 – 45) 37 (27 – 45) 0.456 
Platelet count, (109/L), median (range) 103 (46 – 268) 123 (26 – 192) 0.775 
Serum -fetoprotein, g/ml, median 
(range) 
15 (2 – 3951) 9 (5 – 8840) 0.813 
Previous hepatectomy 13 (33.3) 4 (40) 0.721 
Previous radiofrequency ablation 9 (23) 5 (50) 0.093 
Previous chemoembolization 22 (56.4) 8 (80) 0.278 
Tumor size, cm, median (range) 2.29 (0.9 – 8) 3.75 (1.1 – 5.7) 0.013* 
Number of tumors, median (range) 1 (1 – 2) 1 (1 – 2) 0.727 
Pre-HIFU Lipiodol deposition 14 (35.8) 7 (70) 0.076 
Use of artificial pleural effusion 25 (64.1) 6 (60) 1.000 
Values are numbers of patients (percentage) unless stated otherwise. 
*Statistically significant. 
 Table 4.  Univariate analysis on possible prognostic factors affecting the overall survival 
after HIFU. 
 
Factors 1-year survival 
rate, % 
3-year survival 
rate, % 
P value 
Age   < 60 (n = 15) 
      > 60 (n = 34) 
100 
82.1 
67.9 
60.8 
0.222 
Sex   Male (n = 40) 
      Female (n = 9) 
89.9 
77.8 
64.3 
50 
0.244 
Hepatitis B infection   Yes (n = 37) 
                    No (n = 12) 
91.7 
75 
66.9 
56.3 
0.698 
Hepatitis C infection   Yes (n = 7) 
                    No (n = 42) 
71.4 
90.3 
47.6 
68.3 
0.512 
Child-Pugh liver function class A  (n = 41) 
                     class B  (n = 8) 
90.2 
75 
68.5 
33.3 
0.028* 
Serum bilirubin < 23 mol/L (n = 35) 
             > 23 mol/L (n = 14) 
88.6 
85.7 
71.8 
49.6 
0.741 
Serum albumin < 30 g/L (n = 5) 
             > 30 g/L (n = 44) 
80 
88.5 
30 
66.7 
0.102 
Platelet count  < 150 ×109/L (n = 35) 
             > 150 ×109/L (n = 14) 
85.5 
92.9 
61.8 
66.8 
0.888 
Serum -fetoprotein < 200 g/ml (n = 37) 
                 > 200 g/ml (n = 12) 
91.7 
75 
57.5 
75 
0.831 
Previous hepatectomy  Yes (n = 17) 
                    No (n = 32) 
100 
81.1 
72.5 
57.9 
0.103 
Previous RFA        Yes (n = 14) 
                   No (n = 35) 
85.7 
79 
77.9 
56.2 
0.543 
Previous TACE       Yes (n = 30) 
                    No (n = 19) 
86.5 
89.5 
61.6 
77.4 
0.891 
Tumor size         < 3.0 cm ( n = 32) 
                   3.0 cm (n = 17) 
96.9 
70.1 
57.9 
61.3 
0.474 
No. of tumors      Solitary (n = 41) 
                 Multiple (n = 8) 
90.1 
75 
63.4 
62.5 
0.352 
Pre-HIFU Lipiodol deposition Yes (n = 21) 
                         No (n = 28) 
85.7 
89.3 
60 
76.9 
0.744 
Use of artificial pleural effusion Yes (n = 31)               
                          No (n = 18) 
87 
88.9 
60.5 
70 
0.971 
Primary technique effectiveness Yes (n = 39) 
No (n = 10) 
92.3 
68.6 
68.1 
45.7 
0.249 
Secondary technique effectiveness Yes (n = 42) 
                             No (n = 7) 
92.9 
53.6 
66.8 
35.7 
0.060 
*Statistically significant. RFA, radiofrequency ablation. TACE, transarterial chemoembolization
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